Pregabalin for the treatment of generalized anxiety disorder: an update
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
A PREVIOUS REVIEW SUMMARIZED WHAT WAS THEN KNOWN ABOUT THE POTENTIAL ROLE OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH GENERALIZED ANXIETY DISORDER (GAD): this review provides an update on its pharmacological properties and presumed mechanism of action, the liability for abuse, and efficacy and tolerability in patients with GAD. Pregabalin has a similar molecular structure to the inhibitory neurotransmitter gamma amino butyric acid (GABA) but its mechanism of action does not appear to be mediated through effects on GABA. Instead, its anxiolytic effects may arise through high-affinity binding to the alpha-2-delta sub-unit of the P/Q type voltage-gated calcium channel in "over-excited" presynaptic neurons, thereby reducing the release of excitatory neurotransmitters such as glutamate. The findings of randomized controlled trials and meta-analyses together indicate that pregabalin is efficacious in both acute treatment and relapse prevention in GAD, with some evidence of an early onset of effect, and broad efficacy in reducing the severity of psychological and physical symptoms of anxiety. It also has efficacy as an augmenting agent after non-response to antidepressant treatment in GAD. Continuing vigilance is needed in assessing its potential abuse liability but the tolerability profile of pregabalin may confer some advantages over other pharmacological treatments in the short term for treatment in patients with GAD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The size and burden of mental disorders and other disorders of the brain in Europe 2010
Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jönsson, B., Olesen, J., Allgulander, C., Alonso, J., Faravelli, C., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.018 · Cited by 3,754
Beesdo, K., Knappe, S., & Pine, D. S. (2009) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2009.06.002 · Cited by 1,703 · cited 1×
“It typically emerges gradually 4 and the onset of the full syndromal disorder is later than in other anxiety disorders.”
Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies
Wittchen, H.-U., & Jacobi, F. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.04.012 · Cited by 1,503 · cited 1×
“9%.(2) It is probably the most common anxiety disorder among the elderly population.”
Bruce, S. E., Yonkers, K. A., Otto, M. W., Eisen, J. L., Weisberg, R. B., Pagano, M., Shea, M. T., & Keller, M. B. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.6.1179 · Cited by 963
Eroglu, Ç., Allen, N. J., Susman, M. W., O'Rourke, N. A., Park, C. Y., Özkan, E., Chakraborty, C., Mulinyawe, S. B., Annis, D. S., Huberman, A. D., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.025 · Cited by 893
Bandelow, B., Sher, L., Bunevicius, R., Hollander, E., Kasper, S., Zohar, J., Möller, H.-J., WFSBP Task Force on Mental Disorders in Primary Care, & WFSBP Task Force on Anxiety Disorders, O. A. P. (2012) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2012.667114 · Cited by 428
Nitschke, J. B., Sarinopoulos, I., Oathes, D. J., Johnstone, T., Whalen, P. J., Davidson, R. J., & Kalin, N. H. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07101682 · Cited by 375 · cited 1×
“A functional MRI study found evidence of increased anticipatory activity in the dorsal amygdala after cues indicating forthcoming aversive and neutral pictures, suggesting an “overall enhanced anticipatory emotional responsiveness in GAD” (that is, preparing for difficult challenges ahead).(32) Investigations of the p…”
Wittchen, H.-U., Carter, R. M., Pfister, H., Montgomery, S. A., & Kessler, R. C. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015060-00002 · Cited by 299
Dugas, M. J., Marchand, A., & Ladouceur, R. (2005) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2004.02.002 · Cited by 258 · cited 1×
“…of investigations has shown that individuals with GAD scan the environment for cues suggesting threat; 27 develop worrying in an attempt to solve problems; 28 may use worrying to avoid physical symptoms of anxiety; 29 find it hard to tolerate uncertainty or ambiguity; 30 and “worry about worrying”.”
Metacognitive therapy for generalized anxiety disorder: An open trial
Wells, A., & King, P. (2006) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/j.jbtep.2005.07.002 · Cited by 254
Hettema, J. M., Prescott, C. A., & Kendler, K. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.9.1581 · Cited by 224 · cited 1×
“GAD shares a common heritability with major depression(16) and with the personality trait of “neuroticism”.(17,18) The 5-hydroxtryptamine (5-HT; serotonin) transporter gene-linked polymorphic region short/short genotype is more frequent in patients with GAD,(19) and variations in two sub-types of the glutamic acid dec…”
Azapirones for generalized anxiety disorder
Chessick, C. A., Allen, M. H., Thase, M. E., Batista Miralha da Cunha, A. A., Kapczinski, F., Silva de Lima, M., & dos Santos Souza, J. J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006115 · Cited by 144
TYRER, P., SEIVEWRIGHT, H., & JOHNSON, T. (2004) · Psychological Medicine · doi:10.1017/s0033291704002569 · Cited by 119 · cited 1×
“GAD and major depression have a similar degree of functional impairment(8,9) but patients with comorbid major depression and GAD have a more severe and prolonged course of illness and greater impairment.(10) GAD is also common among patients with “medically unexplained” chronic pain,(11) chronic physical ill-health,(1…”
Neonatal maternal separation enhances central sensitivity to noxious colorectal distention in rat
Chung, E. K. Y., Zhang, X., Li, Z., Zhang, H., Xu, H., & Bian, Z. (2007) · Brain Research · doi:10.1016/j.brainres.2007.03.047 · Cited by 86
Effect of short-term SSRI treatment on cognitive bias in generalised anxiety disorder
Mogg, K., Baldwin, D. S., Brodrick, P., & Bradley, B. P. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1902-y · Cited by 74
Self-citationBaldwin, D. S., Allgulander, C., Bandelow, B., Ferre, F., & Pallanti, S. (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.624548 · Cited by 69 · cited 1×
“It has been recommended as a potential first-line treatment in patients with GAD(122) and in psychiatric practice is commonly used both as a first-line treatment and as a second-line treatment either on its own or as an augmentation agent.(123) Because of its beneficial effects in reducing sleep disturbance and somati…”
Self-citationBobes, J., Rubio, G., Terán, A., Cervera, G., López-Gómez, V., Vilardaga, I., & Pérez, M. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2010.12.004 · Cited by 57 · cited 1×
“114–117 A switch study in which patients receiving long-term benzodiazepines were randomized to 12 weeks of double-blind treatment with either flexible-dose pregabalin or placebo while the dosage of benzodiazepines was tapered down, followed by a 6-week benzodiazepine-free phase, found that…”
Unschuld, P. G., Ising, M., Specht, M., Erhardt, A., Ripke, S., Heck, A., Kloiber, S., Straub, V., Brueckl, T., Müller‐Myhsok, B., et al. (2009) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30938 · Cited by 40 · cited 6×
“17,18 The 5-hydroxtryptamine (5-HT; serotonin) transporter gene-linked polymorphic region short/short genotype is more frequent in patients with GAD, 19 and variations in two sub-types of the glutamic acid decarboxylase gene may increase the susceptibility to anxiety disorders, including GAD.”
Influential
Cited by
Treatment of anxiety disorders
Bandelow, B., Michaelis, S., & Wedekind, D. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.2/bbandelow · Cited by 811
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“Discontinuation symptoms after abrupt withdrawal of pregabalin have been reported, as has the abuse of pregabalin generally in individuals with a history of other substance abuse: but the relative potential for developing tolerance and abuse, when compared to with medications, is not established [IV] (Baldwin et al.,…”
BackgroundInfluentialSelf-citationEfficacy of treatments for anxiety disorders: a meta-analysis
Bandelow, B., Reitt, M., Röver, C., Michaelis, S., Görlich, Y., & Wedekind, D. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000078 · Cited by 555
“with withdrawal symptoms and abuse in individuals with multisubstance abuse; however, the relative abuse potential, compared with other medications, has not been established (Baldwin et al., 2013).”
BackgroundLöscher, W., & Klein, P. (2021) · CNS Drugs · doi:10.1007/s40263-021-00827-8 · Cited by 367
Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132
Metadata
- Authors
- Baldwin, D., Ajel, Nowak, Rafiq, & Masdrakis, V.
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2013-06
- Volume
- 9
- Pages
- 883
- ISSN
- 1176-6328 (ISSN-L)
- OpenAlex
- W2025511246
- Cited by
- 125
- References
- 18
- FWCI
- 10.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.